Ethanol 98% Solution ( DrugBank: Ethanol )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
279巨大静脈奇形(頚部口腔咽頭びまん性病変)2

279. 巨大静脈奇形(頚部口腔咽頭びまん性病変)


臨床試験数 : 15 薬物数 : 24 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 105
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-011276-29-FR
(EUCTR)
21/08/200915/05/2009Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with congenital venous malformations (CVM): pharmacokinetic, pharmacodynamic and clinical study.Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with congenital venous malformations (CVM): pharmacokinetic, pharmacodynamic and clinical study. patients with congenital venous malformations (CVM)Product Name: Ethanol gel
Product Code: L0122
Other descriptive name: ETHANOL (96 PER CENT)
Trade Name: Dehydrated Alcohol (Absolute Alcohol) BP for Injection
Product Name: Dehydrated Alcohol (Absolute Alcohol) BP for Injection
Other descriptive name: ETHANOL BP
ORFAGENNULLNot RecruitingFemale: yes
Male: yes
24Phase 2France
2NCT00462462
(ClinicalTrials.gov)
May 200716/4/2007Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.Congenital Venous MalformationDrug: Ethanol 96% Gel;Drug: Ethanol 98% SolutionOrfagenFDA Office of Orphan Products DevelopmentCompleted12 YearsN/AAll32Phase 2United States;France